Menu
← Oncology Approval Tracker
FDA DECISION ·
Fruzaqla
fruquintinib · Takeda Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin and irinotecan regimens and anti-VEGF therapy. Patients with RAS wild-type disease should have received anti-EGFR therapy if medically appropriate.
LAMPGEN ANALYSIS
Why it matters
This decision introduced a later-line targeted option after several established systemic therapies.
What research teams should watch
Audit prior regimens, RAS testing and the rationale when anti-EGFR treatment was medically inappropriate.
PRIMARY RECORDS